Capricor Therapeutics (CAPR)
(Delayed Data from NSDQ)
$5.24 USD
-0.24 (-4.38%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $5.24 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value B Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CAPR 5.24 -0.24(-4.38%)
Will CAPR be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for CAPR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CAPR
Capricor Therapeutics (CAPR) Reports Q1 Loss, Misses Revenue Estimates
Verano Holdings Corp. (VRNOF) Reports Q1 Loss, Tops Revenue Estimates
CAPR: What are Zacks experts saying now?
Zacks Private Portfolio Services
SurModics (SRDX) Q2 Earnings and Revenues Top Estimates
Wall Street Analysts Predict a 218.18% Upside in Capricor (CAPR): Here's What You Should Know
How Much Upside is Left in Capricor (CAPR)? Wall Street Analysts Think 229.15%
Other News for CAPR
Capricor Therapeutics Announces Positive 3-Year Efficacy Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy
Capricor Therapeutics announces 3-year efficacy results from HOPE-2 OLE study
PTC Therapeutics rallies 18% on EU authorization update for Translarna
Capricor Therapeutics stock rises, Oppenheimer initiates coverage at Outperform
Novavax, Capricor Therapeutics, Arcutis Biotherapeutics among healthcare movers